Antibody Discovery News and Research

RSS

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.

19 Sep 2013

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.

12 Sep 2013

Adimab Scores Two Deals And Some Milestone Payments

...

22 Aug 2013

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

In a serendipitous discovery, scientists at The Scripps Research Institute have found a way to turn bone marrow stem cells directly into brain cells.

23 Apr 2013

Integral Molecular releases MPS antibody discovery platform

ntegral Molecular, Inc., a leader in membrane protein reagents and services, announces the launch of its Membrane Protein Solutions antibody discovery platform.

23 Apr 2013

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patient's immune system to seek out and attack cancerous cells and tumors.

15 Feb 2013

Dyax fourth quarter total revenues increase to $16.0 million

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

13 Feb 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

Trellis, OMT enter collaboration to generate human antibodies

Trellis Bioscience LLC and Open Monoclonal Technology, Inc. today announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMT's OmniRat platform.

8 Oct 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of two major grants for the development of monoclonal antibody therapeutics against nosocomial infections.

11 Sep 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.

21 Jul 2012

Merck, OMT announce new antibody discovery collaboration

Open Monoclonal Technology, Inc. (OMT) today announced an antibody discovery collaboration with Merck KGaA. OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats to generate antibodies against several targets selected by Merck KGaA.

9 Jul 2012

Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.

15 Jun 2012

Igenica raises $33M in Series C round of funding

Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.

12 Jun 2012

CRT, BioInvent partner to identify new therapeutic antibodies in oncology

BioInvent International AB and Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

12 Jun 2012

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.

16 May 2012

New discovery platform for antigen-specific monoclonal antibodies

Cell Signaling Technology, Inc. of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies.

From Cell Signaling Technology 11 May 2012

Integral Molecular receives U.S. patent for methodology that generates Lipoparticles

Integral Molecular, a leader in membrane protein reagents and services, announces the issuance of a key patent protecting its methodology for generating Lipoparticles, which provide highly-concentrated membrane proteins in their native conformation for antibody and drug discovery applications focused on membrane protein targets such as G protein-coupled receptors (GPCRs), ion channels, and transporters.

4 May 2012